DiaMedica updates AIS trial protocol, delays interim readout to Q4 2025; Q3 R&D spend rises

DiaMedica Therapeutics Inc.

Expanded ReMEDy2 trial to include thrombolytic non-responders; interim analysis sample size increased to 200 from 144.
Top-line interim results now expected Q4 2025 (prior Summer 2025); interim analysis delayed.
Q3 2024 R&D expenses $5.0M (up from $3.3M YoY); G&A flat at $1.9M.
Cash, equivalents and investments $50.2M as of Sep 30, 2024; cash runway into Q3 2026.
Preeclampsia Phase 2 IST received SAHPRA approval; first patient dosed; top-line Part 1A results expected H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.